Shreya Kanodia, PhD

Associate Director, Administration
Department of Biomedical Sciences
Samuel Oschin Comprehensive Cancer Institute


Dr. Shreya Kanodia is a cancer immunologist who has worked on developing therapeutic cancer vaccines since 1999. Trained as a tumor immunologist, she has over 15 years of life science research experience, including working on Phase I/II clinical trials for cancer therapy. Dr. Kanodia currently serves as Assistant Professor and Director of Grants Management in the Department of Biomedical Sciences and Associate Director for Administration in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center in Los Angeles, CA as well as Adjunct Assistant Professor at the University of Hawaii Cancer Center, Honolulu, HI. Her research interests lie in understanding the pathogenesis of mesothelioma and using this understanding to develop novel diagnostics and therapeutics. In addition to performing research, she has successfully established and operated a number of for-profit and not-for-profit organizations. She established the United States operations of Advanced Microdevices Pvt Ltd, a privately owned multinational corporation, and served as the Co-Owner/Director for Business Development. She also co-founded Advanced Bioscience Technologies LLC and functioned as the Co-Owner/Chief Financial Officer. She holds a Bachelors degree in Biochemical Engineering from the Indian Institute of Technology, Kharagpur in West Bengal, India and a Ph.D. in Immunology/Cancer Biology from the University of Texas M. D. Anderson Cancer Center in Houston, Texas.

Research Interest

Her research interests lie in understanding the pathogenesis of mesothelioma and using this understanding to develop novel diagnostics and therapeutics.

Scientific Activities


•(2009) NIH Travel Award – International Papillomavirus Society
•(2008) USC Norris Cancer Center Distinguished Merit Award
•(2006) Achievement Rewards for College Scientists Foundation Fellowship
•(2006) NIH Travel Award – International Papillomavirus Society
•(2004) Vivian L. Smith Outstanding Young Immunologist Award (2nd place)
•(2003) American Legion Auxiliary Fellowship (competitive renewal)
•(2003) Sowell-Huggins/Sylvan Rodriguez Fellowship
•(2002) American Society of Hematology Travel Award
•(2002) MD Anderson Cancer Center Trainee Excellence Award
•(2001) GSBS Student Travel Award (winner for 2 consecutive years)
•(2001) Womens Travel Scholarship Award

Professional Memberships:

•(2010-Present) Member, Association of American Cancer Institutes (AACI)
•(2010-Present) Member, Cancer Center Administrators Forum (CCAF)
•(2012-Present) Member, American Association Of Cancer Research (AACR)
•(2012-Present) Member, National Council Of University Research Administrators (NCURA)
•(2013-Present) Member, Association Of Cancer Executives (ACE)



1. Rivera Z, Ferrone S, Wang X, et al.CSPG4 As a Target of Antibody-Based Immunotherapy For Malignant Mesothelioma. Clinical Cancer Research. 2012; 18(19): 5352-5363. doi:10.1158/1078-0432.CCR-12-0628.
2. Kanodia S, Kast WM. Perspectives on prophylactic and therapeutic vaccination for HPV-induced lesions. In: Human Papillomavirus Vaccines. Future Medicine Ltd, London, UK. 2011.
3. Carbone M, Baris IY, Bertino P, et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma.Proc Natl Aca Sci USA. 2011; 108: 13618-13623. doi:10.1073/pnas.1105887108.
4. Kanodia S, Wieder ED, Lu S, et al. High-avidity PR1-CTL contribute to the maintenance of remission in IFN-sensitive CML patients off all therapy. PloS One. 2010; 5(7): e11770.
5. Kanodia S, Da Silva DM, Karamanukyan, T, Bogaert, L, Fu Y-X and Kast WM. Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus type 16 E6 and E7 induces significant tumor regression. Cancer Research. 2010; 70(10): 3955-3964. doi:10.1158/0008-5472.CAN-09-3773.
6. Kanodia S, Kast WM. The immunoevasive nature of persistent oncogenic HPV infection and the development of cervical cancer. Touch Briefings. 2010.
7. Gray A, Kanodia S, Hubby B, et al. Prostate cancer immunotherapy administered at an early stage of carcinogenesis prior to the establishment of tumorassociated immunosuppression yields superior long-term survival in TRAMP mice. Vaccine. 2009; 27(6): G52-G59. doi:10.1016/j.vaccine.2009.09.106.
8. Kanodia S, Kast WM. Peptide vaccines for cancer – Realizing their potential. Expert Review of Vaccines. 2008; 7(10): 1533-1545. doi: 10.1586/14760584.7.10.1533.
9. Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. International Journal of Cancer. 2008; 122(2): 247-259. doi:10.1002/ijc.23252
10. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Current Cancer Drug Targets. 2007; 7(1): 79-89. doi:10.2174/156800907780006869
11. Molldrem JJ, Lee PP, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high avidity leukemia-specific T-cells. Journal of Clinical Investigation. 2003; 111(5): 639-647. doi:10.1172/JCI16398.
12. Molldrem JJ, Kant S, Jiang W, Lu S. The basis of T cell-mediated immunity to chronic myelogenous leukemia. Oncogene. 2002; 21(56): 8668-8673. doi: 10.1038/sj.onc.1206093
13. Sarkar S, Sreekanth B, Kant S, Banerjee R, Bhattacharya BC. Production and optimization of microbial lipase. Bioprocess Engineering. 1998; 19(1): 29-32.